Study of NXP900 for advanced solid tumors
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be advanced, spread, or growing despite standard treatments.
- You must have at least one tumor that can be measured on scans.
- You must be able to perform daily activities without help (ECOG score 0-1).
- You cannot have had chemotherapy, radiation, or other cancer drugs within the last 28 days before starting NXP900.
- If you have had brain metastases, they must be stable without recent progression.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, XTX501, for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if the drug can help shrink tumors or slow their growth.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
This trial tests a new drug called LXP1788 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how it affects the body.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.